{"transactions":[{"id":2383648,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Convertible Note","published_at":"2022-02-23T01:01:11.000Z","date":"2022-02-18","kind":"other","acquired":true,"price":20000,"reported_value":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $20,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $20,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $20,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $20,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-22-001214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316822001214/ownership.xml","form_type":"4"}},{"id":2383647,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130167,"kind":"person","name":"FELCYN GLORIA","position":1,"cik":"0001233397","reported_name":"FELCYN GLORIA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Note","published_at":"2022-02-23T01:00:40.000Z","date":"2022-02-18","kind":"other","acquired":true,"price":25000,"reported_value":25000,"ownership":{"direct":false,"nature":"Self as trustee of GLORIA H. FELCYN 1998 SEPARATE PROPERTY TRUST"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $25,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $25,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $25,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $25,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-22-001213","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316822001213/ownership.xml","form_type":"4"}},{"id":2383646,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130166,"kind":"person","name":"GARNICK ROBERT L","position":1,"cik":"0001214124","reported_name":"GARNICK ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Note","published_at":"2022-02-23T01:00:13.000Z","date":"2022-02-18","kind":"other","acquired":true,"price":50000,"reported_value":50000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-22-001212","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316822001212/ownership.xml","form_type":"4"}},{"id":2383645,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Note","published_at":"2022-02-23T00:55:16.000Z","date":"2022-02-18","kind":"other","acquired":true,"price":50000,"reported_value":50000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-22-001211","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316822001211/ownership.xml","form_type":"4"}},{"id":2383644,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2022-02-23T00:54:37.000Z","date":"2022-02-18","kind":"other","acquired":true,"price":10000,"reported_value":10000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $10,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $10,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $10,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $10,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-22-001210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316822001210/ownership.xml","form_type":"4"}},{"id":2721849,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130166,"kind":"person","name":"GARNICK ROBERT L","position":1,"cik":"0001214124","reported_name":"GARNICK ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Note","published_at":"2021-05-10T20:05:36.000Z","date":"2021-05-07","kind":"other","acquired":true,"price":100000,"reported_value":100000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on May 7, 2021 in exchange of $100,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on May 7, 2021 in exchange of $100,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on May 7, 2021 in exchange of $100,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on May 7, 2021 in exchange of $100,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See Footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-21-001855","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821001855/ownership.xml","form_type":"4"}},{"id":2721848,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130167,"kind":"person","name":"FELCYN GLORIA","position":1,"cik":"0001233397","reported_name":"FELCYN GLORIA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Note","published_at":"2021-05-10T20:05:11.000Z","date":"2021-05-07","kind":"other","acquired":true,"price":25000,"reported_value":25000,"ownership":{"direct":false,"nature":"Self as trustee of GLORIA H. FELCYN 1998 SEPARATE PROPERTY TRUST"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on May 7, 2021 in exchange of $25,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on May 7, 2021 in exchange of $25,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on May 7, 2021 in exchange of $25,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on May 7, 2021 in exchange of $25,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377, representing $21 million divided by the number of fully diluted shares of Common Stock outstanding, including common stock reversed for issuance under the Company's Series B Convertible Voting Preferred Stock and the Company's 2020 Equity Incentive Plan as of the issuance date."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See Footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-21-001854","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821001854/ownership.xml","form_type":"4"}},{"id":2735107,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-04-30T19:58:00.000Z","date":"2021-04-29","kind":"grant","acquired":true,"shares":5357,"price":2.8,"value":14999.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSU's granted under the 2020 Mosaic ImmunoEngineering Omnibus Incentive Plan as part of the reporting person's consulting agreement executed on April 29, 2021. RSUs will vest 100% on August 31, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":5357,"derivative":{"exercise_date":"2022-08-31","underlying":"Common Stock","underlying_shares":5357},"source":{"system":"sec-edgar","filing":"0001683168-21-001650","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821001650/ownership.xml","form_type":"4"}},{"id":2891263,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting CSO"}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2021-01-29T22:32:42.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":56000,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":570870},"source":{"system":"sec-edgar","filing":"0001683168-21-000323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000323/ownership.xml","form_type":"4"}},{"id":2891262,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting CSO"}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2021-01-29T22:32:42.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":161000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1641252},"source":{"system":"sec-edgar","filing":"0001683168-21-000323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000323/ownership.xml","form_type":"4"}},{"id":2891261,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting CSO"}}],"security":"Common Stock","published_at":"2021-01-29T22:32:42.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":570870,"ownership":{"direct":false,"nature":"By spouse."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."}],"balance_after":570870,"source":{"system":"sec-edgar","filing":"0001683168-21-000323","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000323/ownership.xml","form_type":"4"}},{"id":2891260,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting CSO"}}],"security":"Common Stock","published_at":"2021-01-29T22:32:42.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":1641252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."}],"balance_after":1641252,"source":{"system":"sec-edgar","filing":"0001683168-21-000323","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000323/ownership.xml","form_type":"4"}},{"id":2891259,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2021-01-29T22:32:17.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":161000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1641252},"source":{"system":"sec-edgar","filing":"0001683168-21-000322","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000322/ownership.xml","form_type":"4"}},{"id":2891258,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-29T22:32:17.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":1641252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."}],"balance_after":1641252,"source":{"system":"sec-edgar","filing":"0001683168-21-000322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000322/ownership.xml","form_type":"4"}},{"id":2891257,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2021-01-29T22:31:51.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":161000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1641252},"source":{"system":"sec-edgar","filing":"0001683168-21-000321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000321/ownership.xml","form_type":"4"}},{"id":2891256,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-29T22:31:51.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":1641252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."}],"balance_after":1641252,"source":{"system":"sec-edgar","filing":"0001683168-21-000321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000321/ownership.xml","form_type":"4"}},{"id":2891255,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130166,"kind":"person","name":"GARNICK ROBERT L","position":1,"cik":"0001214124","reported_name":"GARNICK ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2021-01-29T22:30:04.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":356794},"source":{"system":"sec-edgar","filing":"0001683168-21-000320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000320/ownership.xml","form_type":"4"}},{"id":2891254,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130166,"kind":"person","name":"GARNICK ROBERT L","position":1,"cik":"0001214124","reported_name":"GARNICK ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-29T22:30:04.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":356794,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."}],"balance_after":356794,"source":{"system":"sec-edgar","filing":"0001683168-21-000320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000320/ownership.xml","form_type":"4"}},{"id":2938629,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130167,"kind":"person","name":"FELCYN GLORIA","position":1,"cik":"0001233397","reported_name":"FELCYN GLORIA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-12-18T16:12:57.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":26087,"price":3.3,"value":86087.1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan for non-employee Board compensation. RSUs will vest 100% on December 16, 2021, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":26087,"derivative":{"exercise_date":"2021-12-16","underlying":"Common Stock","underlying_shares":26087},"source":{"system":"sec-edgar","filing":"0001683168-20-004370","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004370/ownership.xml","form_type":"4"}},{"id":2943536,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:18:26.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":37772,"price":3.3,"value":124647.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as a long-term incentive grant equal to 25% of reporting person's annual base salary. RSUs will vest 100% on August 31, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":80164,"derivative":{"exercise_date":"2022-08-31","underlying":"Common Stock","underlying_shares":37772},"source":{"system":"sec-edgar","filing":"0001683168-20-004324","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004324/ownership.xml","form_type":"4"}},{"id":2943535,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:18:26.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":42392,"price":3.3,"value":139893.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as part of the reporting person's annual base salary. RSUs will vest 100% on August 31, 2021, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":42392,"derivative":{"exercise_date":"2021-08-31","underlying":"Common Stock","underlying_shares":42392},"source":{"system":"sec-edgar","filing":"0001683168-20-004324","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004324/ownership.xml","form_type":"4"}},{"id":2943534,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:18:03.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":43479,"price":3.3,"value":143480.7,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as a long-term incentive grant equal to 25% of reporting person's annual base salary. RSUs will vest 100% on August 31, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":108697,"derivative":{"exercise_date":"2022-08-31","underlying":"Common Stock","underlying_shares":43479},"source":{"system":"sec-edgar","filing":"0001683168-20-004323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004323/ownership.xml","form_type":"4"}},{"id":2943533,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:18:03.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":65218,"price":3.3,"value":215219.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as part of the reporting person's annual base salary. RSUs will vest 100% on August 31, 2021, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":65218,"derivative":{"exercise_date":"2021-08-31","underlying":"Common Stock","underlying_shares":65218},"source":{"system":"sec-edgar","filing":"0001683168-20-004323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004323/ownership.xml","form_type":"4"}},{"id":2943532,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":144629,"kind":"person","name":"JOHNSON CARLTON M","position":1,"cik":"0001244103","reported_name":"JOHNSON CARLTON M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:17:39.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":26087,"price":3.3,"value":86087.1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan for non-employee Board compensation. RSUs will vest 100% on December 16, 2021, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":26087,"derivative":{"exercise_date":"2021-12-16","underlying":"Common Stock","underlying_shares":26087},"source":{"system":"sec-edgar","filing":"0001683168-20-004322","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004322/ownership.xml","form_type":"4"}},{"id":2943529,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130166,"kind":"person","name":"GARNICK ROBERT L","position":1,"cik":"0001214124","reported_name":"GARNICK ROBERT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:17:12.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":26087,"price":3.3,"value":86087.1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan for non-employee Board compensation. RSUs will vest 100% on December 16, 2021, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":26087,"derivative":{"exercise_date":"2021-12-16","underlying":"Common Stock","underlying_shares":26087},"source":{"system":"sec-edgar","filing":"0001683168-20-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004321/ownership.xml","form_type":"4"}}]}